Alerts
Want to monitor ATYR?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ATYRWant to monitor ATYR?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ATYRatyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd.